SCHEMBL3939752

SCHEMBL3939752

Nc1ncc2cccc(N)c2n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK1 P49759 4/20 0.47
DYRK1A Q13627 1/20 0.47
CDK5 Q00535 2/20 0.40
CDK5R1 Q15078 2/20 0.40
CYP3A4 P08684 2/20 0.39
LMNA P02545 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
PDPK1 O15530 1/20 0.39
HSD17B10 Q99714 2/20 0.38
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38
TSHR P16473 1/20 0.38
KEAP1 Q14145 1/20 0.38
FGFR1 P11362 3/20 0.38
HTR3A P46098 1/20 0.38
DHFR P00374 2/20 0.37
SRC P12931 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30995668 1.00 CLK1 (0.47) CLK1DYRK1ACDK5CDK5R1CYP3A4
SCHEMBL7705046 0.79 FGFR1 (0.49) CLK1DYRK1ALMNAFGFR1DHFR
SCHEMBL2916502 0.79 FGFR1 (0.50) CLK1DYRK1ALMNAHSD17B10ALDH1A1
SCHEMBL1041168 0.79 PLAU (0.55) CLK1DYRK1ACYP3A4CYP1A2CYP2C9
SCHEMBL23003121 0.79 CLK1 (0.44) CLK1DYRK1ACDK5CDK5R1PDPK1
SCHEMBL25450062 0.79 BACE1 (0.55) CLK1DYRK1ACDK5CDK5R1PDPK1
SCHEMBL25449349 0.79 CLK1 (0.41) CLK1DYRK1ACDK5CDK5R1FGFR1
SCHEMBL22136018 0.75 CLK1 (0.62) CLK1DYRK1ACDK5CDK5R1CYP3A4
SCHEMBL24615646 0.75 P2RX3 (0.49) CLK1DYRK1ACYP3A4LMNACYP1A2
SCHEMBL1039857 0.75 MCHR1 (0.59) CYP3A4ALDH1A1KDM4ETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108602780-A New compound and its pharmacologically acceptable salt 明治制果药业株式会社 2018-09-28 CN claimed
CN-108602780-A New compound and its pharmacologically acceptable salt 明治制果药业株式会社 2018-09-28 CN disclosed
EP-2894157-B1 Condensed cyclic compound and organic light-emitting device including the same SAMSUNG ELECTRONICS CO LTD (KR) 2018-04-04 EP disclosed
US-20090203667-A1 PENTADIENAMIDE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-08-13 US disclosed
CN-101489989-A Pentadiene amide derivative KYOWA HAKKO KIRIN CO LTD (JP) 2009-07-22 CN disclosed
EP-2050734-A1 PENTADIENAMIDE DERIVATIVE Kyowa Hakko Kirin Co., Ltd. (JP) 2009-04-22 EP disclosed
CN-101309586-A Thiazole compounds as fungicides BAYER CROPSCIENCE AG (DE) 2008-11-19 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203667-A1 PENTADIENAMIDE DERIVATIVES PRMT1, REN, NGLY1 CLK1 4240/4885DYRK1A 481/4885CDK5 607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.